ImmunityBio Inc. Stock
Price
Target price
€2.56
€2.56
7.690%
0.183
7.690%
€10.00
04.06.25 / Tradegate
WKN: A2QQ2E / Name: ImmunityBio / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Loading data...
Your prediction
ImmunityBio Inc. Stock
ImmunityBio Inc. dominated the market today, gaining €0.18 (7.690%).
With 1 Sell predictions and 1 Buy predictions the community sentiment towards the ImmunityBio Inc. stock is not clear.
With a target price of 10 € there is potential for a 290.17% increase which would mean more than doubling the current price of 2.56 € for ImmunityBio Inc..
So far the community has only identified positive things for ImmunityBio Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of ImmunityBio Inc. in the next few years
Pros
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
B****
Cons
?
G***** c******* t* c**********
?
S********** s********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of ImmunityBio Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| ImmunityBio Inc. | 7.690% | 6.729% | 6.063% | -58.204% | -14.085% | -23.010% | -63.817% |
| Krystal Biotech | 1.080% | 2.627% | -21.519% | -23.498% | -24.277% | 125.980% | - |
| Ardelyx Inc. | -4.460% | -1.371% | -5.399% | -45.672% | -30.473% | 451.614% | -47.298% |
| Evolus Inc | -1.180% | -0.585% | -18.269% | -26.087% | -19.048% | -34.615% | 94.064% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2024-08-01
When diving into the financials of ImmunityBio, a company operating in the Biotechnology & Medical Research sector, the overall impression is that of a company grappling with significant challenges. Key metrics such as earnings, profitability, and valuation ratios suggest a period of struggle, which may be indicative of a firm still in the development stages of its products. This analysis aims to break down both the merits and downfalls of the current financial landscape to better understand ImmunityBio's potential trajectory.
Market Capitalization
Revenue Generation
